Company Overview and News

The Zacks Analyst Blog Highlights: Etsy, eBay, Amazon and PetMed Express

10h zacks
Chicago, IL – April 20, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Etsy (ETSY - Free Report) , eBay (EBAY - Free Report) , Amazon (AMZN - Free Report) and PetMed Express (PETS - Free Report) .
Upvote Downvote

Supreme Court Can't Solve the Internet Sales Tax Problem

2018-04-19 zacks
As the Supreme Court discusses the pros and cons of overriding the precedent set in the case of Quill vs. North Dakota, small sellers and platforms like Etsy (ETSY - Free Report) and eBay (EBAY - Free Report) that support them have started doing all they can to rouse public opinion against it.
Upvote Downvote

Alkermes's stock soars 21% premarket after FDA accepts NDA for review

2018-04-16 marketwatch
Shares of Alkermes PLC soared 21% in premarket trade Monday, after the biopharmaceutical company said the Food and Drug Administration accepted for review the company's new drug application (NDA) for its treatment of major depressive disorder (MDD). The acceptance comes after the FDA had initially issued a "refusal to file" letter for the MDD treatment, ALKS 5461, on March 30. The stock had plunged 22% on April 2, when the news of the letter was released.
Upvote Downvote

Semtech (SMTC) Hits 52-Week High on Bullish Growth Trends

2018-04-11 zacks
Semtech Corporation’s (SMTC - Free Report) shares hit a new 52-week high of $43.35 on Apr 10, closing a shade lower at $42.80. Barring minor hiccups, Semtech’s share price has steadily been on an uptrend. The stock has the potential for further price appreciation with long-term earnings growth expectation of 5%.
Upvote Downvote

Amazon Extends Two-Hour Whole Foods Delivery Service to LA

2018-04-11 zacks Inc. (AMZN - Free Report) continues to expand its two-hour Whole Food delivery Service. Los Angeles is the latest addition to the list of countries receiving this service.
Upvote Downvote

Add These 7 GARP Stocks to Enhance Your Portfolio Returns

2018-04-11 zacks
Growth at a reasonable price or GARP is an excellent way for investors to make some quick gains. This strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. The GARP approach leads to the identification of stocks that are priced below the market or any reasonable target determined by fundamental analysis. These stocks also have solid prospects in terms of cash flow, revenues, earnings per share (EPS) and so on.
Upvote Downvote

Alibaba Partners With E-Glober, Expands Cloud to Turkey

2018-04-10 zacks
Alibaba Group Holding Limited (BABA - Free Report) is further expanding its cloud presence beyond its stronghold, China, quite aggressively.
Upvote Downvote

Strong Product Portfolio Aids AMETEK (AME), Risks Persist

2018-04-09 zacks
On Apr 6, we issued an updated research report on technology firm, AMETEK Inc. (AME - Free Report) .The stock carries a Zacks Rank #3 (Hold).
Upvote Downvote

Adobe (ADBE) Promotes Murphy as New Chief Financial Officer

2018-04-09 zacks
Adobe Systems Inc. (ADBE - Free Report) recently announced that John Murphy will be taking up responsibilities as its executive vice president and Chief Financial Officer (CFO), effective Apr 9.
Upvote Downvote

GlaxoSmithKline Is A Good Buy - Cramer's Lightning Round (4/6/18)

2018-04-09 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, April 6.
Upvote Downvote

Cramer's lightning round: BlackBerry's CEO doesn't get enough credit

2018-04-06 cnbc
BlackBerry: "That's OK. We like the intellectual property. We like the turn. [BlackBerry CEO John] Chen doesn't get enough credit."
Upvote Downvote

Amazon (AMZN) Green Lights Lorena to Prime Original Content

2018-04-06 zacks Inc.’s (AMZN - Free Report) film production division, Amazon Studios, has green lit a documentary series, Lorena.
Upvote Downvote

Here's Why You Should Add (ALRM) to Your Portfolio

2018-04-05 zacks Holdings, Inc. (ALRM - Free Report) is currently one of the top-performing stocks in the technology sector, and an increase in share price and strong fundamentals signal its bull run. Therefore, if you haven’t taken advantage of the share price appreciation yet, it’s time you add the stock to your portfolio.
Upvote Downvote

Amazon (AMZN) Plans to Open New Fulfillment Center in Nevada

2018-04-05 zacks Inc. (AMZN - Free Report) plans to expand in North Las Vegas with its fourth Nevada fulfillment center.
Upvote Downvote

Alibaba Rides on New Investments & International Growth

2018-04-05 zacks
On Apr 4, we issued an updated research report on Alibaba Group Holding Limited (BABA - Free Report) .
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 716382106